We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Hyaluronic Acid Agents Could Prevent Adhesions After Gynecologic Surgery

By HospiMedica staff writers
Posted on 18 Jun 2007
Adhesion formation after fertility-preserving gynecologic surgery may be decreased with the use of hyaluronic acid-based fluid agents, according to a new study.

Researchers at the University of Sheffield (United Kingdom; www.shef.ac.uk) conducted a meta-analysis of available studies from the Cochrane menstrual disorders and subfertility group specialized register of controlled trials, The Cochrane central register of controlled trials, MEDLINE, and EMBASE and identified four randomized controlled trials of hyaluronic acid fluid agents compared with no treatment or placebo in women undergoing fertility-preserving gynecologic surgery.

An association was observed between the use of hyaluronic acid agents and a decrease in the prevalence of adhesions at second-look laparoscopy. More...
Patients treated with hyaluronic acid also had a decreased chance of deterioration of preexisting adhesions. However, the researchers concluded that the severity of adhesions should not be used as a surrogate marker for future fertility potential, and therefore, future studies should include live birth rate as a primary outcome measure and have adequate follow-up periods. The study was published in the May 2007 issue of Fertility and Sterility.

"Intraperitoneal adhesions are an important cause of postoperative intestinal obstruction, abdominal discomfort, and infertility,” said lead author Dr. Mostafa Metwally. "Despite careful attention to minimize tissue trauma and ensure hemostasis, pelvic surgery is associated with both de novo adhesion formation and reformation.”

Hyaluronic acid (also called hyaluronan or hyaluronate) is a glycosaminoglycan found in lubricating proteoglycans of the synovial fluid, vitreous humors, cartilage, blood vessels, skin, and the umbilical cord. It is one of the chief components of the extracellular matrix, and contributes significantly to cell proliferation and migration.


Related Links:
University of Sheffield

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Gas Consumption Analyzer
Anesthetic Gas Consumption Analyzer
Digital Color Doppler Ultrasound System
MS22Plus
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The researchers grew pancreatic tissue (above) so it incorporated a mesh-like electronic network (red). Cells within the tissue produce insulin (green). (Photo courtesy of Penn Medicine)

‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes

Type 1 diabetes destroys insulin-producing islet cells, forcing patients to rely on lifelong insulin therapy or scarce organ transplants. Although lab-grown pancreatic tissue offers a promising alternative,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.